The Association Between BRAF Mutation Class and Clinical Features in BRAF-Mutant Chinese Non-Small Cell Lung Cancer Patients

被引：0
|
作者：
Lin, Q. [1 ]
Zhu, H. [2 ]
Li, Y. [1 ]
Zhang, H. [3 ]
Ding, H. [4 ]
Qian, J. [5 ]
Han-Zhang, H. [6 ]
Lin, J. [6 ]
Xiang, J. [6 ]
机构：
[1] Wenzhou Med Univ, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Wenzhou, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[3] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China
[4] Ningbo Diagnost Pathol Ctr, Ningbo, Zhejiang, Peoples R China
[5] Nanjing Med Univ, Affiliated Suzhou Hosp, Suzhou, Peoples R China
[6] Burning Rock Biotech, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Chinese; braf; NSCLC;
D O I：
10.1016/j.jtho.2019.08.735
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-20
引用
收藏
页码：S363 / S363
页数：1
相关论文
共 50 条
  • [31] Brief report: High incidence of peridiagnosis thromboembolic events in patients with BRAF-mutant lung cancer
    Aparicio, Inmaculada
    Iranzo, Patricia
    Reyes, Roxana
    Bote, Helena
    Saigi, Maria
    Bringas, Marianela
    Bosch-Barrera, Joaquim
    Corral, Jesus
    Aparisi, Francisco
    Ruffinelli, Jose C.
    Jimenez, Beatriz
    Lage, Yolanda
    Lopez-Castro, Rafael
    Majem, Margarita
    Vazquez, Sergio
    Artal, Angel
    Rodriguez-Perez, Angel
    Lazaro-Quintela, Martin
    Torres, Jose Miguel Sanchez
    Reguart, Noemi
    Cucurull, Marc
    Gil-Bazo, Ignacio
    Camps, Carlos
    Nadalj, Ernest
    del Barrio, Anabel
    Garrido, Pilar
    Domine, Manuel
    Alvarez, Rosa
    Munoz, Andres J.
    Calles, Antonio
    THROMBOSIS RESEARCH, 2023, 232 : 133 - 137
  • [32] BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective
    Yan, Ningning
    Guo, Sanxing
    Zhang, Huixian
    Zhang, Ziheng
    Shen, Shujing
    Li, Xingya
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [33] PREDICTIVE VALUE OF KRAS AND BRAF MUTATIONS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH CHEMOTHERAPY
    Dingemans, Anne-Marie
    Smit, Egbert F.
    Heideman, Danielle
    Mellema, Wouter
    Derks, Jules
    Van, Robertjan Suylen
    Thunnissen, Erik
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1044 - S1044
  • [34] Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
    Gautschi, Oliver
    Milia, Julie
    Cabarrou, Bastien
    Bluthgen, Marie-Virginia
    Besse, Benjamin
    Smit, Egbert F.
    Wolf, Juergen
    Peters, Solange
    Frueh, Martin
    Koeberle, Dieter
    Oulkhouir, Youssouf
    Schuler, Martin
    Curioni-Fontecedro, Alessandra
    Huret, Benjamin
    Kerjouan, Mallorie
    Michels, Sebastian
    Pall, Georg
    Rothschild, Sacha
    Schmid-Bindert, Gerald
    Scheffler, Matthias
    Veillon, Remi
    Wannesson, Luciano
    Diebold, Joachim
    Zalcman, Gerard
    Filleron, Thomas
    Mazieres, Julien
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (10) : 1451 - 1457
  • [35] Association of mutation profiles with metastasis in patients with non-small cell lung cancer
    Li, Yingxue
    Zheng, Zheng
    Wang, Li
    Han, Lin
    Du, Ying
    Zhang, Xuedong
    Liu, Xia
    Xie, Jiaping
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [36] Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer
    Huang, Yingying
    Jia, Wenzhuo
    Zhao, Gang
    Zhao, Yunbo
    Zhang, Shuai
    Li, Zhongkang
    Wu, Guoju
    CHINESE CLINICAL ONCOLOGY, 2024, 13 (01)
  • [37] A literature review of a meta-analysis of BRAF mutations in non-small cell lung cancer
    Chimbangu, Clint Taonaishe
    Xi, Li
    Ya, Zhou
    Jiayue, Zhao
    Xiao, Meng
    Ying, Wang
    Xingxu, Yu
    Liu, Xiaomei
    MEDICINE, 2024, 103 (08) : E34654
  • [38] Clinical and molecular characteristics, therapeutic strategy, and prognosis of non-small cell lung cancer patients harboring primary and acquired BRAF mutations
    Feng, Xiangran
    Xiang, Yi
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2025, 55
  • [39] Correlation between clinicopathological features and KRAS, NRAS, and BRAF mutation status in Chinese colorectal cancer patients
    Zhu, Xiaoli
    Meng, Xianke
    Xiang, Wenqiang
    Dai, Weixing
    Bai, Qianming
    Sheng, Weiqi
    Lu, Yongming
    Qi, Peng
    Wu, Lijing
    Cai, Guoxiang
    Zhou, Xiaoyan
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (05): : 2839 - 2845
  • [40] Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer
    Li, Hui
    Zhang, Yongchang
    Xu, Yanjun
    Huang, Zhiyu
    Cheng, Guoping
    Xie, Mingyin
    Zhou, Zichao
    Yu, Yangyang
    Xi, Wenjing
    Fan, Yun
    CELL DEATH & DISEASE, 2022, 13 (12)
12345